Intellectual property

UK Supreme Court awards Professor Shanks £2m compensation for invention of ‘outstanding benefit’ after 13 year court battle

Rafi Allos

In Shanks v Unilever Plc and others, the UK Supreme Court has, for the first time, handed down a decision on employee compensation for patented inventions. The Supreme Court overturned the previous decisions in the case and decided that Professor Shanks, an employee of Unilever’s UK research subsidiary, CRL, had made a patented invention that Read More

China: NMPA Seeks Comments on Draft Regulations of Drug Registration, Manufacturing and Distribution

David Shen

On 30 September 2019, the Chinese National Medical Products Administration (the NMPA) published three sets of draft regulations seeking public comment. They are the Draft Drug Registration Regulations, the Draft Manufacturing Regulations and the Draft Drug Distribution Regulations. The Ministry of Justice further updated these Draft Regulations on 15 October 2019 and is seeking public Read More

Cannabinoid patenting – a rolling stone?

Marc Döring

Late in 2018, medicinal cannabis[1] was downgraded from Schedule 1 to Schedule 2 (medically allowed) in the Misuse of Drugs Regulations in the UK. The resulting flurry of activity in the mainstream news media about the use of cannabinoids and similar substances has been inescapable. Whilst there is arguably still a lot of hype around Read More

China: Amendment to Drug Administration Law

David Shen

On 26 August 2019, the China’s National People’s Congress passed the amended Drug Administration Law (the Amended DAL) which will take effect on 1 December. The new law brings in some changes while codifying many existing practices. We summarise in this article the key highlights, including intellectual property related rules, of the Amended DAL. 1. Redefine Read More

Dutch medicines regulator updates policy on how to carve out patented indications

Lars Braams

On 8 May 2019, the Dutch Medicines Agency (CBG/MEB) published a revised policy on generic manufacturers’ ability to carve out patented indications from their product information (that is, leaflet and summary of product characteristics). This new policy is a direct result of the CJEU’s preliminary ruling in Staat der Nederlanden v Warner-Lambert Company LLC (Case Read More